Seminars in Immunopathology

Papers
(The TQCC of Seminars in Immunopathology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Complement & disease: out of the shadow into the spotlight106
Fine mapping with epigenetic information and 3D structure88
CAF-immune cell crosstalk and its impact in immunotherapy83
Thymus and autoimmunity83
Harnessing the n+1 dimensions of single-cell omics data for the prediction and prevention of human diseases78
Halting targeted and collateral damage to red blood cells by the complement system77
Learning cell identity in immunology, neuroscience, and cancer74
Systemic innate myeloid responses to acute ischaemic and haemorrhagic stroke73
The fetal programming effect of maternal immune activation (MIA) on the offspring’s immune system59
Proteomics to study cancer immunity and improve treatment59
Causes and costs of global COVID-19 vaccine inequity56
Vascular galectins in tumor angiogenesis and cancer immunity53
Monocyte dysregulation: consequences for hepatic infections47
Single-cell high-dimensional imaging mass cytometry: one step beyond in oncology42
Disease pathogenesis and barrier functions regulated by group 3 innate lymphoid cells42
Th17 cells in the liver: balancing autoimmunity and pathogen defense41
The eosinophil and its role in physiology and disease: news and views38
Development of vascular disease models to explore disease causation and pathomechanisms of rare vascular diseases35
Neuroimaging is the new “spatial omic”: multi-omic approaches to neuro-inflammation and immuno-thrombosis in acute ischemic stroke35
Circadian rhythms in adaptive immunity and vaccination35
Adaptive immunity, chronic inflammation and the clock34
Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriers32
Tumor microenvironment antigens32
Clonal hematopoiesis and vascular disease31
Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target31
Novel immune cell phenotypes in spondyloarthritis pathogenesis31
MAIT cells in liver inflammation and fibrosis31
Recent advances on the role of cytotoxic T lymphocytes in the pathogenesis of spondyloarthritis30
Functional heterogeneity of CD4+ T cells in liver inflammation30
Neuroimmune interactions in health and disease29
The role of circulating cell-free DNA as an inflammatory mediator after stroke29
Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors29
Chronoimmunology: from preclinical assessments to clinical applications28
Beyond GWAS: from simple associations to functional insights28
Regulatory T lymphocytes as a therapy for ischemic stroke27
Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors27
The mucosal immune system and IgA nephropathy27
Role of polyamines in intestinal mucosal barrier function26
Genetics and functional genomics of multiple sclerosis26
The overlooked bacterial pandemic26
Intracellular galectin interactions in health and disease25
Revisiting transplant immunology through the lens of single-cell technologies25
The role of circadian clock pathways in viral replication23
Advances in manufacturing chimeric antigen receptor immune cell therapies23
Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy22
The twilight zone: plasticity and mixed ontogeny of neutrophil and eosinophil granulocyte subsets22
COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells21
Metabolic Regulation in the Induction of Trained Immunity21
Diseases of blood vessels: Immune system involvement in vasculitis and vasculopathy21
Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy21
The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies20
Neuropathogenesis of HIV-1: insights from across the spectrum of acute through long-term treated infection20
Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 1620
0.032909154891968